BD Diagnostics – Infectious Disease products are at the forefront of rapid, nucleic acid-based systems for the detection and identification of infectious agents. Leveraging the advantages of rapid, molecular-based diagnostics, the BD GeneOhm™ and BD MAX™ line of products assists in transforming health-care by enabling earlier and more definitive clinical decisions, improving both the quality and the cost of patient care. BD uniquely provides a complete menu of products to help detect and manage MRSA, with the BD GeneOhm™ MRSA ACP assay and the BBL™ CHROMagar® MRSA II test. Through these products, BD is dedicated to offering laboratories and clinicians state-of-the-art tests that can provide results.
The current BD GeneOhm™ product portfolio includes four rapid, nucleic acid amplification assays: the BD GeneOhm™ StrepB Assay for rapid detection of Group B Streptococcus DNA, the BD GeneOhm™ MRSA ACP Assay for detection of methicillin-resistant Staphylococcus aureus DNA directly from nasal specimens, the BD GeneOhm™ StaphSR Assay for the simultaneous detection and differentiation of Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) directly from positive blood cultures, and the BD GeneOhm™ Cdiff Assay for the rapid detection of C. difficile toxin B gene (tcdB) in human liquid or soft stool specimens from patients suspected of having Clostridium difficile infection (CDI).
The BD MAX™ System is a next generation platform for molecular testing which automates cell lysis, nucleic acid extraction, PCR set-up, amplification and detection. The BD MAX™ System is designed to provide maximum testing flexibility, efficiency and scalability for molecular testing. The BD MAX system has been designed as a versatile workstation for a broad range of molecular testing applications, offering high utility with a planned menu of IVD assays.
CHROMagar is a registered trademark of Dr. Alan Rambach.